MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

E260

CAS No. : 1241537-79-0

MCE 国际站：E260

产品活性：E260 是一种 Fer/FerT 激酶抑制剂。

研究领域：Others

作用靶点：Others

In Vitro: E260 is a Fer and FerT inhibitor, which selectively evokes metabolic stress in cancer cells by imposing mitochondrial dysfunction and deformation, and onset of energy-consuming autophagy which decreases the cellular ATP level. To demonstrate that E260 directly targets Fer and FerT, an in vitro kinase assay is performed using a purified kinase domain (KD)-containing fragment of these enzymes. This analysis demonstrates the direct inhibitory effect of E260 on this domain as reflected by the significantly decreased auto-phosphorylation level of the Fer/FerT KD when incubated with ATP and increasing concentrations of E260. Moreover, computational analysis of E260 docking in the modeled whole Fer protein reveals that the highest scored binding mode of E260 to Fer falls in the ATP-binding pocket of the enzyme’s KD. To measure the dissociation constant (K_d) of E260 from Fer/FerT KD, a microscale thermophoresis (MST) test is performed using ascending concentrations of E260. This analysis corroborates the direct binding of E260 to Fer/FerT KD and determines a K_d of 0.85 µM. To examine the effect of the E260 micellar formulation on Fer in malignant cells, the kinase is immunoprecipitated from untreated and from E260-treated SW620 CC cells. When applied to metastatic grade IV SW620 CC cells, which are serum starved for 16 h and treated with 3 mM H₂O₂ to activate Fer, E260 exhibits inhibitory effects on the Fer-kinase activity as is reflected by suppressed auto-phosphorylation activity of the enzyme. To characterize the effect of E260 on malignant cells, metastatic SW620 cells are treated with E260 followed by analysis of viability. Onset of death is observed in the E260-treated cells, with an EC₅₀ value of 400 nM after 24 h of treatment and an EC₅₀ of 300 nM after 48 h. E260 exhibits an EC₅₀ of 3.2 µM after 72 h treatment of non-metastatic PANC-1 cells, which are derived from a primary pancreatic ductal carcinoma. Moreover, the maximum death level of these cells after 72 h of treatment with E260 is about 70% following treatment with 4 µM E260. In comparison, SU.86.86 which are metastatic ductal carcinoma cells, prove to be more susceptible to E260 with an EC₅₀ of 1.1 µM after 72 h of treatment and 100% death level imposed by 2 µM E260.

In Vivo: E260 suppresses xenografts progression in vivo. The pharmacokinetic (PK) profile of E260 is determined in mice. E260 exhibits a T_1/2 of 175 min in the blood, and a volume of distribution of 4244 mL/kg suggesting an efficient distribution of the compound in the animal tissues. To evaluate the efficacy of E260 on tumor growth, SW620 cells are subcutaneously introduced into immuno-compromised “Nude” mice. Administration of E260 leads to a significant attenuation of tumor progression throughout the experiment, and to a 10-fold decrease in average tumor volume after 22 days of treatment. To further demonstrate the anti-cancer activity of E260 in vivo, mice bearing SW48 cells derived xenografts are treated with E260 and the tumor progression profiles are determined. Mice treated with E260 demonstrate a 5-6-fold attenuation in tumors progression when compared to the control treated group.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Anti-Cancer Compound Library  |  Anti-diabetic Compound Library  |  Targeted Diversity Library  |  Heterocyclic Compound Library  |  Antitumor agent-67  |  Catechin 7-O-β-D-glucopyranoside  |  Carbobenzoxyproline  |  ATR-IN-9  |  TBTDC  |  Peucenin 7-O-methyl ether  |  6-Hydroxy-4-methylcoumarin  |  AMT-NHS  |  Nylidrin hydrochloride  |  D-(+)-Fucose  |  OVA Peptide (323-339)  |  Secretin (swine)  |  Bletilloside A  |  Transcriptional Intermediary Factor 2 (TIF2) (740-753)  |  Pep-1 (uncapped)  |  Aspochalasin M  |  Dihydrofuran-3(2H)-one  |  2,6-Difluoropyridine  |  BPK-29 hydrochloride  |  pppApG  |  MEIS-IN-2  |  2′-O-Methyl-8-methyl guanosine  |  Altertoxin I  |  Lithospermoside  |  Acitazanolast  |  FLAG peptide  |  [Des-Tyr1]-Met-Enkephalin  |  α-Carotene  |  myo-Inositol trispyrophosphate hexa-triethylamine  |  Myt1-IN-2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。